CSPC Group announced that the Phase III clinical trial of amxetine hydrochloride enteric tablets developed by the Group for the treatment of patients with depression has reached the predetermined main efficacy endpoints. The test results have both significant statistical differences and clear clinical benefits. The Montgomery-Eisberg Depression Scale score on the 8th weekend of HA1406 treatment was significantly superior to the baseline change value compared to placebo, and numerically superior to positive control drugs. It is safe and is expected to be a first-line treatment for depression.

CSPC Group announced that the Phase III clinical trial of amxetine hydrochloride enteric tablets developed by the Group for the treatment of patients with depression has reached the predetermined main efficacy endpoints. The test results have both significant statistical differences and clear clinical benefits. The Montgomery-Eisberg Depression Scale score on the 8th weekend of HA1406 treatment was significantly superior to the baseline change value compared to placebo, and numerically superior to positive control drugs. It is safe and is expected to be a first-line treatment for depression.